Prepared remarks
Good day, everyone. My name is Leila, and I will be your conference operator today. At this time, I would like to welcome you to the Kura Oncology first quarter 2026 financial results earnings call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a Q&A session. If you would like to ask a question during this time and if you have joined via the webinar, please use the raise hand icon, which can be found at the bottom of your webinar application. To allow everyone the opportunity to participate, we ask that you please limit yourself to one question and then reenter the queue for any follow ups. At this time, I would like to turn the call over to Greg Mann, Senior Vice President of Investor Relations and Corporate Affairs of Kura Oncology. Please go ahead.
Thank you, Leila. Good afternoon, and welcome to Kura Oncology's first quarter 2026 conference call. Joining the call today are Dr. Troy Edward Wilson, President and Chief Executive Officer; Brian T. Powl, Chief Commercial Officer; Mollie Leoni, Chief Medical Officer; and Tom Doyle, Senior Vice President, Finance and Accounting. We remind you that today's discussion will include forward-looking statements based on current expectations. Such statements represent management's judgment as of today and may involve risks and uncertainties that cause actual results to differ materially from expected results. Please refer to Kura's filings with the SEC which are available from the SEC or on the Kura Oncology website for information concerning risk factors that could affect the company. With that, I will turn the call over to Troy.
Thank you, Greg. Good afternoon, everyone. Kura is at an inflection point. What we have been building over the last several years is now showing up clearly in the clinic, in the market, and in the way physicians are making treatment decisions. Our first commercial launch is off to a strong start. Our phase 3 programs are ahead of plan, and over the next 12 to 24 months, we expect a steady flow of data that we believe will define leadership in the menin inhibitor class. Most importantly, we are executing with focus, discipline, and a very clear strategy. Let me start with Comzifty. In our first full quarter of launch, we generated $5.8 million in net product revenue, ahead of expectations. But what matters more to us is what is underneath those numbers: seeing repeat prescriptions. We are seeing broad uptake and use expand across treatment centers. We are seeing increasing payer preference and we are seeing early instances of physicians switching patients from other menin inhibitors to Comzifty. That tells us something important. This is not just a class story anymore. Physicians are starting to differentiate based on product profile and we believe Comzifty is standing out. We see that differentiation coming from a combination of compelling efficacy, a predictable safety profile, simple and convenient dosing, and potential for broad combinability. In real world practice, these things matter, and they are driving how physicians choose therapy. It is early, but based on what we are seeing, we believe Comzifty is well positioned to emerge as a leader in the treatment of adult patients with relapsed or refractory NPM1-mutant AML. At the same time, we are not building this as a single-indication product. Our focus is to expand ziftomenib across the AML treatment continuum and establish it as a backbone therapy in combination. This year, we expect to generate multiple data readouts to support that strategy, including updated data from our 7+3 combination in newly diagnosed AML, a publication of our venetoclax/azacitidine combination, and initial data from our gilteritinib combination in relapsed and refractory AML patients with NPM1 and FLT3 co-mutations. Taken together, these data sets are designed to answer a simple question: can Comzifty be used broadly, safely, and effectively in combination across AML? Based on what we have seen so far, we believe the answer will be yes. In parallel, our frontline phase 3 program, COMMODORE-17, is progressing ahead of plan with strong enrollment for both studies across leading global sites. Our one-stop shop design is doing exactly what we intended: accelerating execution without compromising rigor. Beyond AML, we continue to build a broader pipeline with meaningful upside. Darlafarnib is a good example. The data we have generated reinforced its mechanism and potential to overcome resistance to targeted therapies. We have additional combination data expected this year, including in KRAS G12C-mutated cancers, where we think there is an opportunity to open up new treatment approaches across large solid tumor indications. So when we step back, we think Kura is in a very strong position. We have a commercial product that is gaining traction and beginning to differentiate in the real world. We have a pipeline with multiple anticipated near-term clinical catalysts that can expand that opportunity significantly, and we have the balance sheet to execute our strategy and reach key value-creating milestones. The menin inhibitor class in AML is still early. The next one or two years will determine how it evolves and who leads. Based on what we are seeing today in the clinic and in the market, we are confident in our ability to play a leading role in shaping that future. With that, I will turn it over to Brian.
Thanks, Troy. I am very encouraged by Comzifty's performance in the first full quarter of launch. And although we are pleased by the first quarter results, we are even more encouraged by the underlying trends driving that revenue. Our early momentum reflects three core strengths: strong preparation and an experienced commercial team and, most importantly, a clearly differentiated product profile defined by efficacy, safety, combinability and convenient dosing. Our commercial strategy is focused on three priorities: drive broad awareness of Comzifty's differentiated profile, deliver strong and consistent quarter-over-quarter growth, and establish leadership in relapsed/refractory NPM1-mutant AML, a $350 million to $400 million market opportunity. In the first quarter, we generated $5.8 million in net product revenue, with 85 new patient starts and nearly 160 total prescriptions. Patients were treated across approximately 60 activated accounts including ziftomenib trial sites, other menin inhibitor experience centers, and accounts new to menin inhibitors. More importantly, we are seeing clear signs of growing physician adoption. First, repeat prescriptions and expanding use across treatment settings indicate growing physician confidence with Comzifty in real-world practice. Second, following our approval, we have observed physicians switching patients from other menin inhibitors to Comzifty. Although still early, this is a meaningful signal that physicians are making active treatment decisions based on the product profile. Third, we are aware of early physician-initiated use of Comzifty in combination with commonly used agents, including venetoclax/azacitidine and with gilteritinib in FLT3 co-mutated patients. This physician-initiated use reinforces our belief that ziftomenib has the potential to be a highly combinable backbone for use across AML patient populations. Feedback from physicians, pharmacists and nurses consistently highlights the practice advantages of Comzifty, particularly its dosing simplicity and convenience for patients. We believe these are important factors in real-world treatment decisions when monotherapy efficacy is viewed as similar. Collectively, these dynamics point to a clear conclusion. Increasingly, physicians, pharmacists and nurses are selecting Comzifty, which offers strong efficacy with a well-characterized and manageable safety profile and convenient once-daily dosing compatible with concomitant therapies. What we describe as efficacy without compromise. Turning to access. We secured coverage at parity or better for more than 93% of covered lives, with no label restrictions. Achieving this level of access this early in launch, particularly as a second-to-market therapy, reflects the strong payer recognition of Comzifty's value. We are also seeing favorable formulary positioning and step edit dynamics. I am thrilled to report more than ten plans covering more than 12 million lives have placed Comzifty in a favorable policy position. These decisions reflect payer recognition of Comzifty's differentiated profile and the predictability of its cost in managing patients in this setting. Operationally, execution remains strong. Time from prescription to patient receipt is approximately three days, ensuring rapid access to therapy. And our field teams in collaboration with Kyowa Kirin are driving strong engagement across both academic and community settings. Looking at the bigger picture, the combination of repeat prescriptions, broad payer preferences, expanding real-world use, and early instances of switching gives us confidence that COMZIFTY is not just participating in the menin inhibitor class, but is increasingly defining its leadership position in the NPM1 market. The success we are seeing in this initial monotherapy setting is an important first step and reflects our foundational advantage of delivering strong efficacy with a predictable safety profile and convenient dosing that in our view represents efficacy without compromise. Importantly, this early momentum lays the foundation for our next phase of growth as we expand into combination and frontline settings. I will now turn it over to Mollie.
Thank you, Brian. In 2026, we expect a continued steady cadence of clinically meaningful data for ziftomenib and darlafarnib. Our strategy for ziftomenib is focused on one clear objective: establishing it as a highly active and broadly combinable backbone therapy across the AML treatment landscape, supported by our registrational clinical programs spanning multiple lines of therapy and patient populations. As treatment paradigms evolve, physicians are increasingly looking for therapies that could be safely and effectively combined with existing standards of care, and ziftomenib is specifically designed to address that need. At the upcoming EHA meeting in June, we plan to present updated data from ziftomenib in combination with 7+3 in newly diagnosed NPM1-mutant and KMT2A-rearranged AML. This updated dataset will include extended follow-up with a median of approximately 16 months, including treatment course and response durability. We also expect to publish data showcasing venetoclax and azacitidine in combination with ziftomenib in relapse or refractory NPM1-mutant AML. These data expand upon our presentation at ASH 2025, where we reported a striking 70% composite CR rate in patients without prior venetoclax exposure. This is an important regimen as venetoclax/azacitidine remains a widely used standard of care. In parallel, we are advancing combinations with FLT3 inhibitors. As a reminder, FLT3 mutations occur in approximately one third of AML patients, and notably 50% of NPM1-mutant patients have FLT3 co-mutations. We anticipate preliminary data in the second half of the year from ziftomenib in combination with gilteritinib in relapsed or refractory NPM1-mutant, FLT3-mutated AML. We are also evaluating ziftomenib in combination with quizartinib in the newly diagnosed setting. As a whole, these data are building a consistent picture: ziftomenib can be integrated across multiple treatment approaches without compromising safety or activity in clinical studies. An attribute we believe will be essential for long-term use in both relapse and frontline settings. Turning to our frontline development program, our COMMODORE-17 trial is an innovative one-stop shop design, which enables simultaneous enrollment into two independent phase 3 trials at each activated site. This streamlined approach is a meaningful differentiator and operational advantage, allowing us to accelerate enrollment while maintaining rigorous study design and execution. We are very pleased with the progress to date. Site activation and enrollment are ahead of projections with strong participation from leading academic centers across the U.S., Europe, and Asia. This level of engagement reflects both the clinical interest in menin inhibition and the confidence investigators have in ziftomenib's profile, particularly its potential to be combined with standard frontline regimens. Beyond AML, we continue to explore the broader opportunity of menin inhibition. Our study evaluating ziftomenib plus imatinib in GIST is progressing well, and we hope to provide updates when appropriate. In addition, we are evaluating the role of menin inhibition in other solid tumors. Turning to darlafarnib, it also continues to make important progress. Recent data presented at the International Kidney Cancer Symposium showed clear proof of mechanism demonstrating activity in cabozantinib-pretreated clear cell renal cell carcinoma, a setting where clinicians would not typically expect to re-induce responses with the same TKI after progression. These findings support the role of the REB mTORC1 resistance pathway and reinforce potential for darlafarnib to restore sensitivity to targeted therapies. Enrollment in the phase 1b portion of the darlafarnib plus cabozantinib trial is now underway. In addition, we intend to present an update on the full phase 1a dataset later this year. We see combinations of FTIs and KRAS inhibitors as a potential next advance for patients. At ASCO, we will present preliminary data evaluating darlafarnib plus adagrasib in KRAS G12C-mutated solid tumors and we look forward to discussing that data at a virtual event on June 3rd. I am incredibly proud of our teams at Kura for the disciplined, focused execution behind these programs. Their cross-functional commitment and operational excellence are helping translate our strategy into meaningful clinical progress for patients. With that, I will turn the call over to Tom for financial updates.
Thank you, Mollie. I am happy to provide a brief overview of our financial results for the first quarter of 2026. Our net product revenue from Comzifty sales was $5.8 million compared to none for the same period in 2025. Collaboration revenue from our Kyowa Kirin partnership was $12.5 million compared to $14.1 million for the same period in 2025. Research and development expenses were $65.3 million compared to $56.0 million for the same period in 2025. The increase was driven by ziftomenib combination trials, including the start of enrollment in our COMMODORE-17 trials in 2025. Selling, general and administrative expenses were $31.6 million compared to $22.8 million for the same period in 2025. This increase was driven by the commercial launch of Comzifty. Net loss for Q1 2026 was $73.3 million compared to a net loss of $57.4 million for the same period in 2025. This includes non-cash stock-based compensation expense of $8.4 million compared to $7.8 million for the same period in 2025. As of March 31, 2026, Kura had cash, cash equivalents and short-term investments of $580.8 million compared to $667.2 million as of December 31, 2025. We are maintaining our previously communicated guidance for collaboration revenue. We expect this to be $45 million to $55 million in 2026, $90 million to $110 million in 2027, and $90 million to $110 million in 2028. This revenue reflects non-cash based accounting recognition of performance obligations under our collaboration agreement with Kyowa Kirin. Current cash, cash equivalents and short-term investments as of 03/31/2026 together with anticipated payments of $180 million under our collaboration agreement with Kyowa Kirin are expected to fund our ziftomenib AML program through the first topline Phase 3 results from COMMODORE-17 anticipated in 2028. With that, I will turn the call back over to Troy.
Thank you, Tom. As I said at the outset, the company is firing on all cylinders. Our first commercial launch is off to a strong start, our phase 3 programs are ahead of plan, and we expect a strong cadence of data over the next 12 to 24 months that will further define leadership for ziftomenib in the menin inhibitor class. With that, we will conclude our prepared comments and we are happy, Leila, to open the call up for questions.
Questions and answers
We will now move to our Q&A session. If you have joined via the webinar, please use the raise hand icon, which can be found at the bottom of your webinar application. When you are called on, please unmute your line and ask your question. We will now pause a moment to assemble the queue. And, again, we ask that you please limit yourself to one question. You are welcome to then reenter. Our first question will come from Li Watsak with Cantor. You may now unmute and ask your question.
Hey, team. This is Stan Bronder on for Lee Watsak. Thanks so much for taking our question, and congrats on the update and the commercial launch. Can you give us some color on how we should think about the duration of treatment with Comzifty early given that it sounds like we have patients on monotherapy as well as some that might be receiving a combination? I would greatly appreciate it. Thank you.
Sure, Stan. Thanks for the question. Let me ask Brian if he can speak to that.
Sure. Thanks, Stan, for the question. I think it is difficult at this point to really give too much detail on duration of treatment, because we have one full quarter. We have reiterated before that our expectation is to get around six months of treatment. What I can say is that we are very pleased, of course, with the number of new patient starts. We think that is really the measurement at this early point in the launch to assess how well we are doing. And I think the 85 new patient starts sets us up well. What we need to do is really track several quarters to get a better sense of that.
Your next question will come from Peter Green with LifeSci Capital.
Hi. This is Peter on for Charles. Congrats on the results team. You mentioned a few times the frontline opportunity and also strong enrollment in COMMODORE-17. In light of the EHA abstracts today, I have a question. I am noticing from last year that complete response rates across both NPM1-mutant and KMT2A-rearranged AML in the frontline for ziftomenib in combination with 7+3 are increasing. I am also noticing that CR MRD negativity is occurring potentially out to 43 weeks in some patients. So with all of that said, what have you learned from COMET-007 about ziftomenib's profile in the frontline, especially over longer-term use? Is there some response deepening happening, or is this just an artifact of including less adverse-risk patients? Thanks.
So I think we have learned foremost that we are using it correctly, and that doing it with this staggered start and a start that enables patients to continue to remain on without having to interrupt or lower dose or discontinue for adverse events is a really powerful way to keep these patients both in a response and have that response deepen over time, and have these patients be able to continue on into some form of continuation treatment, whether that be post-transplant or post-consolidation. We continue to gather more data and we continue to be extremely encouraged that the way we have designed COMET-007, the data we continue to gather from COMET-007 helps us to really reinforce that we have correctly designed COMET-007 and COMMODORE-17 so that we can expect great outcomes for these patients in the frontline as well.
Yeah, Peter, this is Troy. Just to add to Mollie's comments, I agree with everything she said. One of the things you will see at EHA is really that this is probably the most mature set of data in the frontline, and it is really a story of durability and clinical benefit for patients. The data will be updated at presentation, but response rate and MRD negativity are important. We will really draw people's attention, as Mollie said, to the durability. This data is pretty unprecedented and I think very encouraging for the promise of menin inhibitors and the COMMODORE-17 study.
Your next question will come from Jonathan Chang with Leerink Partners.
Hi, guys. Thanks for taking my question. On the Comzifty launch, can you provide more color on what you are seeing in terms of initial combination use and instances of switching from other menin inhibitors? How common is combination use and switching? Thank you.
Yes. Thanks for that question, Jonathan. So, what I can share about the combination use of ziftomenib, of course, as you know, our promotional teams and commercial teams are focusing on promoting on-label use as a monotherapy. But physicians are choosing to use it in combination. The data we are seeing so far is that around 40% of patients are being treated with Comzifty in combination, either with venetoclax/azacitidine or, in FLT3 co-mutated patients, with gilteritinib. That is what we are seeing early on. I think getting to the expectation of how those patients will do is something we will follow over time. Regarding switching, that is something we have observed, especially as two products became available. It reflects that physicians now have a choice among multiple inhibitors and some have chosen to switch patients from another menin inhibitor to give them the opportunity to benefit from Comzifty. That decision could be based on the profile, on efficacy, the safety profile, the simplicity of use — all of those things are what we have heard has resonated from a number of physicians.
Understood. Thanks for taking my question.
Your next question will come from Etzer DeRoute with Barclays. Etzer, feel free to unmute and ask your question.
Greg. Thanks for taking the question. Congrats on the quarter. Just a follow-up on the question: can you comment on the primary reasons patients have been switching from other menin inhibitors? I am not sure how many data points you have at this point, but just wondered if you could comment on that. Thank you.
Yeah. I do not think I can go into the details of each patient that switched, really. Probably more at a high level: we are seeing that physicians now have a choice between multiple inhibitors, and there have been physicians who have chosen to switch those patients from another menin inhibitor to give them the opportunity to benefit from Comzifty. So it could be based on the profile, based on whatever decision the physician feels is appropriate, whether it is efficacy, the safety profile, or the simplicity of use. All of those things are what we have heard has resonated from a number of physicians.
Yeah, Etzer, just to jump in and build on that: the switching is, to some extent, what we expected. I agree with Brian, I do not think it is the most significant aspect. What we draw your attention to is, as Brian said in his prepared remarks, the new patient starts. The other menin inhibitor had approximately 130 new patient starts over a similar early launch period; we had 85 in our first full quarter. That is about 40% of that number in our first full quarter. Given the prior story kind of being winner-take-all, we think we have really strong momentum to take leading market share in NPM1. You are going to see some switching, but where we really think you are going to see it is in new patient starts. Again, use in combination, although not our labeled indication, is physician discretion. Those are some of the elements we draw folks' attention to.
Your next question will come from Reni Benjamin with Citizens.
Good afternoon, guys. Thanks for taking the questions, and congrats on the progress. Maybe just sticking with the new patient starts: any additional color you can provide? Anything regarding gross-to-net dynamics? When you talk about the 157 total prescriptions, are these scripts typically one month on average, or three months on average? How can you give us some sort of details there? And one more on commercialization: you said 60 activated accounts. What is the total number of accounts that you are targeting, to give us a sense as to where we are in the cycle? Thanks.
Sure. Thanks for the question, Reni. With regards to new patient starts, these relapsed/refractory patients fit across accounts: Comzifty trial sites, those with experience with other menin inhibitors, and those who have not had any menin inhibitor experience. What we are seeing is a very strong start this early on, and being able to capture roughly 40% of the new patient starts in our first quarter gives us a lot of confidence that there are patients who may benefit from Comzifty. We expect to continue to see quarter-on-quarter growth, to go deeper into other accounts, and ultimately to become the market leader in this space. Regarding scripts, the scripts are one-month scripts. As for gross-to-net dynamics, those are within normal ranges, in the 20% to 30% range.
Excellent. Thanks very much, guys.
Your next question will come from Roger Song with Jefferies.
Hey, team. Thanks for taking our question. This is Nabeel on for Roger. Encouraged to hear on the open-label combo use — it is 40% in combination. I am curious if you could give us color on how this looks in academic and community settings. And then as we get more data, the venetoclax/azacitidine publication and then the second-half data with the FLT3 combo, do you expect this to evolve, and does Comzifty have any advantage here?
So, I think this combination use is based on a lot of data and physician interest. While we are not actively promoting combination use, the feedback and usage we are seeing reflect the potential for Comzifty to be a strong leader in the relapsed/refractory setting and in frontline as the data matures. The venetoclax/azacitidine publication coming in H1 2026 should help to draw momentum. We have heard from physicians that publication of data is very important. We will work to submit that to guideline bodies where appropriate, but we cannot determine incorporation timing. Also, the ability to combine with FLT3 inhibitors gives us a strong avenue because roughly half of NPM1 patients have FLT3 co-mutations — a potential area where Comzifty's profile may provide advantage.
Your next question will come from Philip Nadeau with TD Cowen.
Good afternoon. Thanks for taking our question, and congrats on the progress. Regarding the frontline data that is going to be at EHA, what measures do you think investigators and physicians will look to most when thinking about adopting menin inhibitors in the frontline? Do you think the most powerful data will be durability of response, progression to transplant, or ultimately overall survival? In your conversations, what are physicians evaluating most prominently as they think about moving menin inhibitors forward? Thanks.
I think it is a combination of all of those things. Ultimately, survival is the primary endpoint — you want these patients to live. There is an ability to get to curative intent with transplant, and we want to be able to expand patients' ability to get to curative intent. Durability will be the best prognostic indicator for our ability to increase survival, and MRD negativity is likely to predict that durability as well. So all of them are extremely important. We are seeing very high response rates: you might expect to see 70 to 80 percent of patients having a complete response with 7+3, and we are seeing things trending higher. You might expect to see about 45 percent of patients with MRD negativity in the bone marrow, and we are seeing results in the higher range. So all signs point to these patients having strong, deep responses and a great chance of an effect on overall survival.
Your next question will come from Salim Syed with Mizuho.
Hey, Greg. Congrats on the quarter, guys, and thanks for taking the question. Just one on that 40% number, Troy: could you comment on the cadence through the quarter? Is that representative of your exit NBRx share for NPM1, or was it higher coming out of the quarter? And similarly, is that trend similar to dynamics you are seeing for the current quarter? Thank you.
Yes, Salim. We are talking about small numbers and there is variability week to week and month to month. Our goal is to be the market leader in relapsed/refractory NPM1, 51% or more. We will push that as high as we can. We are second to market behind another product that has been on the market for about 15 months, and we've taken roughly 40% of new patient starts in the first full quarter. That is what we set out to do. This is just the beginning. We are still learning and educating, but we are very optimistic. Expect us to build on that momentum.
Sure.
As a reminder, if you would like to ask a question, please use the raise hand icon, which can be found at the bottom of your webinar application. Our next question will come from David Dai with UBS.
Greg. Thanks for taking my questions, congrats on the quarter. A few questions from me. One: on that $5.8 million revenue, how much of that is inventory stocking? Two: how should we think about the combo use possibly extending the duration of therapy beyond the six months you mentioned? And lastly, do you think patients will continue to use menin inhibitors beyond progression?
Just a reminder, David, we are trying to limit people to one question. But on the first one, there is not any meaningful stocking.
David, on the durability question: it is difficult to define duration within a first full quarter. Our expectation is around six months of treatment on average, but combination patients will likely have longer durations. We need more time and additional quarters of data to understand how those durations play out across lines of therapy and patient characteristics. Regarding continued use beyond progression, we have seen some spontaneous combination use which we anticipated, and we are pleased to see physicians combining with agents like gilteritinib even before those combination data are fully public. That reflects the perceived combinability of ziftomenib. Ultimately continued use beyond progression will be physician dependent and based on clinical judgment and available data.
Thank you so much for taking the time to answer my questions.
Your next question will come from Daniel Breuns with Lake Street.
Thanks for taking my questions. Congratulations on the strong launch. For ASCO, will we be seeing any monotherapy data there or just combination data for darlafarnib with adagrasib?
We have previously presented the monotherapy data last year, which demonstrated a wide therapeutic window balancing both efficacy and safety, allowing for extensive combinations over time. At ASCO, you will see darlafarnib in combination with the KRAS inhibitor adagrasib. You will see dose escalation data across multiple tumor types including non-small cell lung cancer, pancreatic ductal adenocarcinoma, and colorectal cancer. We are excited to share this combination data as part of our effort to address the REB mTORC resistance pathway and help overcome adaptive and innate resistance for these patients.
Thanks.
Your next question will come from Peter Green with LifeSci Capital.
Hi. This is Peter again on for Charles. You mentioned that the COMMODORE-17 trial is enrolling ahead of schedule. Any more details on that, what you are hearing from investigators? And remind me, how does that change any guidance for potential future readouts?
From investigators, all we hear is excitement. New sites and new regions are getting up and running quickly. Participation in the U.S., Europe, and Asia is extremely strong and has reached that level of strength very quickly. COMET-007 was a great indicator of how quickly we could enroll 200 patients into a Phase 1 trial. The Phase 3 enrollment is going incredibly well, and that was predicted by the enrollment rate we saw in 007.
On the guidance question, Peter, we have not changed anything at this point. We have guided to the initial topline results from the intensive chemotherapy combination in 2028. We might tighten that up as we get closer. I will highlight that we are significantly ahead as far as we can tell the competition in that setting. Even in the venetoclax-ineligible setting, the team is making incredible progress. Credit to Mollie for the one-stop shop design combining two phase 3 trials into a single protocol so that each site activation supports enrollment into two registrational studies, which accelerates the program. Expect continued progress and we will update guidance if and when appropriate.
There are no more questions at this time. I would now like to turn the call over to Troy Edward Wilson for closing remarks.
Thank you, Leila. And thank you all for joining us today. We are encouraged by the early performance of the Comzifty launch, the momentum we are seeing across our clinical programs, and the clarity of our strategy moving forward. With continued commercial execution, multiple clinical catalysts ahead, including EHA and ASCO, and a strong financial position, we believe Kura is well positioned to drive meaningful impact for patients and to create long-term value. We look forward to updating you again soon and to engaging with many of you at our upcoming investor event later this month. Thank you all once again, and we will adjourn.